Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.65 |
| ▸ | HTR2C | P28335 | 9/20 | 0.63 |
| ▸ | QDPR | P09417 | 3/20 | 0.51 |
| ▸ | HTR6 | P50406 | 2/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | MMP3 | P08254 | 1/20 | 0.44 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.43 |
| ▸ | FEN1 | P39748 | 1/20 | 0.43 |
| ▸ | KHK | P50053 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6584948 | 0.82 | SIGMAR1 (0.65) | SIGMAR1HTR2CQDPRHTR6HTR7 | |
| SCHEMBL6586606 | 0.82 | HTR2C (0.60) | SIGMAR1HTR2CQDPRHTR6HTR7 | |
| SCHEMBL3383939 | 0.81 | HTR2C (0.62) | SIGMAR1HTR2CQDPRHTR6HTR7 | |
| SCHEMBL3899585 | 0.81 | SIGMAR1 (0.92) | SIGMAR1HTR2CQDPRHTR6HTR7 | |
| SCHEMBL415545 | 0.80 | SIGMAR1 (1.00) | SIGMAR1HTR2CQDPRHTR6HTR7 | |
| SCHEMBL27007924 | 0.80 | HTR2C (0.50) | SIGMAR1HTR2CQDPRALOX5APFEN1 | |
| Hydrochloric Acid SCHEMBL6371753 | 0.80 | HTR2C (0.64) | SIGMAR1HTR2CQDPRHTR6HTR7 | |
| SCHEMBL6586294 | 0.79 | QDPR (0.65) | SIGMAR1HTR2CQDPRHTR6HTR7 | |
| Bromide SCHEMBL11385943 | 0.79 | SIGMAR1 (0.96) | SIGMAR1HTR2CQDPRHTR6HTR7 | |
| Hydrochloric Acid SCHEMBL446973 | 0.79 | HTR2C (1.00) | SIGMAR1HTR2CQDPRHTR6HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7498344-B2 | Arylpiperidinol and arylpiperidine derivatives and pharmaceuticals containing the same | ASUBIO PHARMA CO., LTD. (JP) | 2009-03-03 | — | — | US | disclosed |
| US-7498344-B2 | Arylpiperidinol and arylpiperidine derivatives and pharmaceuticals containing the same | ASUBIO PHARMA CO., LTD. (JP) | 2009-03-03 | — | — | US | disclosed |
| US-7498344-B2 | Arylpiperidinol and arylpiperidine derivatives and pharmaceuticals containing the same | ASUBIO PHARMA CO., LTD. (JP) | 2009-03-03 | — | — | US | disclosed |
| EP-0867183-B1 | ARYLPIPERIDINOL AND ARYLPIPERIDINE DERIVATIVES AND DRUGS CONTAINING THE SAME | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2004-10-06 | — | — | EP | disclosed |
| US-20040186138-A1 | Arylpiperidinol and arylpiperidine derivatives and pharmaceuticals containing the same | DAIICHI SUNTORY PHARMA CO., LTD. | 2004-09-23 | — | — | US | disclosed |
| US-6706734-B2 | ANTIISCHEMIC AGENTS; ANTICONVULSANTS; HEADACHES | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2004-03-16 | — | — | US | disclosed |
| EP-1036062-B1 | HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE (MMP) INHIBITORS | PFIZER LTD (GB) | 2004-01-02 | — | — | EP | disclosed |
| US-20030130312-A1 | Arylpiperidinol and arylpiperidine derivatives and pharmaceuticals containing the same | ASUBIO PHARMA CO., LTD. (JP) | 2003-07-10 | — | — | US | disclosed |
| US-6495568-B1 | TREATMENT OF TISSUE ULCERATION, WOUND REPAIR AND SKIN DISEASES | WARNER-LAMBERT COMPANY | 2002-12-17 | — | — | US | disclosed |
| US-6455549-B1 | ANTIEPILEPTIC, ANTIISCHEMIC, AND ANTIMIGRAINE AGENTS; CALCIUM OVELOAD SUPPRESSANTS | SUNTORY LIMITED (JP) | 2002-09-24 | — | — | US | disclosed |
| EP-1036062-A1 | HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE (MMP) INHIBITORS | Pfizer Limited (GB) | 2000-09-20 | — | — | EP | disclosed |
| WO-1999029667-A1 | HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE (MMP) INHIBITORS | PFIZER LIMITED (GB) | 1999-06-17 | — | — | WO | disclosed |
| EP-0867183-A1 | ARYLPIPERIDINOL AND ARYLPIPERIDINE DERIVATIVES AND DRUGS CONTAINING THE SAME | SUNTORY LIMITED (JP) | 1998-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130312-A1 | Arylpiperidinol and arylpiperidine derivatives and pharmaceuticals containing the same | KCNH1, KCNH2, NPY1R | SIGMAR1 1167/4885HTR2C 100/4885QDPR 529/4885 |
| US-20040186138-A1 | Arylpiperidinol and arylpiperidine derivatives and pharmaceuticals containing the same | KCNH1, KCNH2, NPY1R | SIGMAR1 1167/4885HTR2C 100/4885QDPR 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.